APOE 3/ 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis

Author： Fukumoto H.   Ingelsson M.   Garevik N.   Wahlund L.-O.   Nukina N.   Yaguchi Y.   Shibata M.   Hyman B.T.   Rebeck G.W.   Irizarry M.C.  

Publisher： Elsevier

ISSN： 0014-4886

Source： Experimental Neurology, Vol.183, Iss.1, 2003-09, pp. : 249-253

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Detrimental Effects of Apolipoprotein E4: Potential Therapeutic Targets in Alzheimer's Disease

By  

Current Alzheimer Research, Vol. 4, Iss. 5, 2007-12 ,pp. : 537-540

Bentham Science Publishers

Access to resources Recommend Favorite

Apolipoprotein E4 as a target for developing new therapeutics for Alzheimer’s disease

By Refolo Lorenzo   Fillit Howard  

Journal of Molecular Neuroscience, Vol. 23, Iss. 3, 2004-10 ,pp. : 151-155

Humana Press, Inc

Access to resources Recommend Favorite

Association of HSV1 and apolipoprotein E-ε4 in Alzheimer's disease

By Itzhaki Ruth F   Dobson Curtis B   Lin Woan-Ru   Wozniak Matthew A  

Journal of NeuroVirology, Vol. 7, Iss. 6, 2001-12 ,pp. : 570-571

Ashgate Publishing Ltd

Access to resources Recommend Favorite

UBQ-8i Polymorphism is not An Independent Risk Factor for Mild Cognitive Impairment and Alzheimer’s Disease in APOE-4 Carriers

By  

Current Alzheimer Research, Vol. 9, Iss. 4, 2012-05 ,pp. : 467-472

Bentham Science Publishers

Access to resources Recommend Favorite

Increased Alzheimer’s Disease Neuropathology is Associated with Type 2 Diabetes and ApoE ε4 Carrier Status

By  

Current Alzheimer Research, Vol. 10, Iss. 6, 2013-01 ,pp. : 654-659

Bentham Science Publishers

Access to resources Recommend Favorite